Clinical trials: Patients With Cancer
Solid Tumor Cancers
A First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours
The purpose of this clinical trial is to investigate the treatment for adult patients suffering from advanced or metastatic solid tumours and has 2 parts to the study: the Phase 1 where ascending doses of the experimental study…
- Trial name
- APM-CT001 (NCT07688148)
- Testing
- TAX2
- Where
- 4 sites in Belgium, France
- Volunteers
- 48 people
- Sponsor
- Apmonia Therapeutics
Mantle Cell Lymphoma
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is an aggressive yet often indolent type of B-cell non-Hodgkin lymphoma (NHL). Rocbrutinib (LP-168) is a novel, highly selective, fourth-generation Bruton's tyrosine kinase (BTK) inhibitor that exhibits…
- Trial name
- NCT07377578
- Testing
- Rocbrutinib, Ibrutinib, Acalabrutinib
- Where
- 2 sites in China
- Volunteers
- 394 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Lung Neoplasm, Carcinoma, Bronchogenic
Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer
In this Phase II clinical trial the investigators will use four human non-small cell lung cancer cell lines that have been previously established in tissue culture laboratory.
- Trial name
- NCT01058785
- Testing
- Lucanix
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- NovaRx Corporation
Non-Hodgkin's Lymphoma, Hodgkin's Disease
A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma
This study was an early-phase trial arranged into two phases. The Phase I portion was a dose-escalation study designed to assess the safety, tolerability and to identify the maximum tolerated dose of SB-743921 in patients with…
- Trial name
- NCT00343564
- Testing
- SB-743921
- Where
- 8 sites in United States, Russia
- Volunteers
- 68 people
- Sponsor
- Cytokinetics
Non-Small Cell Lung Cancer, Ovarian Cancer
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer
Study DNB4987g is a Phase I, multicenter, open label, dose-escalation study of DNIB0600A administered as a single agent by intravenous (IV) infusion every three weeks (q3w) to participants with non-squamous NSCLC or non-mucinous…
- Trial name
- NCT01363947
- Testing
- DNIB0600A
- Where
- 7 sites in United States, Spain
- Volunteers
- 87 people
- Sponsor
- Genentech, Inc.
Leukemia, Lymphocytic, Chronic, B-Cell
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax
The main objective of this trial is to determine the maximum tolerated dose (MTD) of BI 836826 in combination with venetoclax on the basis of dose limiting toxicities (DLTs incidence rate during the MTD evaluation period of the…
- Trial name
- NCT03343678
- Testing
- Venetoclax, BI 836826
- Sponsor
- Boehringer Ingelheim
Patients With Cancer
Radioimmunotherapy With 131I-L19SIP in Patients With Cancer
The aim of this Study Protocol is to provide a basis for the clinical development of 131I-L19SIP as an anti-cancer therapeutic agent, following the promising results of a Phase I study.
- Trial name
- NCT01242943
- Testing
- 131I-L19SIP Radioimmunotherapy (RIT)
- Where
- 4 sites in Italy, United Kingdom
- Volunteers
- 34 people
- Sponsor
- Philogen S.p.A.
Colorectal Neoplasms
A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
After consultation with the Korean Health Authorities, the two Post-Authorization Safety Studies EMR 62202-509 (NCT01082315) and EMR 62241-508 (NCT01075828) were combined within one study protocol EMR 062202-551.
- Trial name
- NCT01082315
- Testing
- Erbitux (Cetuximab)
- Where
- South Korea
- Volunteers
- 730 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Solid Tumor
Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors
This project is a phase Ib clinical trial study evaluating the efficacy and safety of TQB2618 injection combined with TQB2450 injection in patients with advanced solid tumors, the trial plan to enroll 127 subjects, the trial…
- Trial name
- NCT05645315
- Testing
- TQB2618 injection and TQB2450 injection
- Where
- 5 sites in China
- Volunteers
- 127 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumors
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
This was an open label, multicenter, Phase 2 study designed to assess the efficacy and safety of tislelizumab in combination with fruquintinib in participants with advanced or metastatic, unresectable gastric cancer (GC), or…
- Trial name
- NCT04716634
- Testing
- Tislelizumab, Fruquintinib
- Where
- 13 sites in China, South Korea
- Volunteers
- 84 people
- Sponsor
- BeiGene
Solid Tumor, Renal Cell Carcinoma (Kidney Cancer)
A Study of NDI 1150-101 in Patients With Solid Tumors
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as…
- Conditions
- Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05128487
- Testing
- NDI-101150, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 106 people
- Sponsor
- Nimbus Saturn, Inc.
Glioblastoma
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma
This study is an open-label, first-in-human, dose-escalation study of CV09050101 mRNA vaccine (CVGBM) in patients with newly diagnosed "MGMT-unmethylated" Glioblastoma (GBM).
- Trial name
- NCT05938387
- Testing
- CV09050101 mRNA vaccine (CVGBM) 12 μg, CV09050101 mRNA vaccine (CVGBM) 25 μg, CV09050101 mRNA vaccine (CVGBM) 50 μg
- Where
- 13 sites in Belgium, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- CureVac
Head and Neck Squamous Cell Carcinoma
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
- Trial name
- NCT06163534
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- Tempus AI
Gastrointestinal Stromal Tumor
A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors
The study is a prospective single armed, open label phase I study. Patients with advanced or metastatic GIST and tumor progression despite ongoing treatment with second, third or fourth line TKI treatment, and with at least one…
- Trial name
- GIST (NCT02686944)
- Testing
- Intuvax (ilixadencel)
- Where
- Sweden
- Volunteers
- 6 people
- Sponsor
- Mendus
Advanced Cancer, Gastric Cancer
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care.
- Conditions
- Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
- Trial name
- NCT04396821
- Testing
- TST001, Nivolumab Injection [Opdivo], mFOLFOX6
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Neoplasm Malignant
Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients
Primary Objective: In the dose escalation: to determine the maximum tolerated dose (MTD) of SAR125844. In the expansion cohort: to evaluate the preliminary anti-tumoral effect of SAR125844 in patients with measurable and MET gene…
- Trial name
- SARMETA (NCT01657214)
- Testing
- SAR125844
- Where
- 8 sites in Japan, South Korea
- Volunteers
- 70 people
- Sponsor
- Sanofi
Prostate Cancer
A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
The purpose of this trial is to compare the severity of ISRs (Injection Site Reactions) following degarelix subcutaneous (s.c.) administrations with two different injection techniques and intramuscular (i.m.) administration in…
- Trial name
- NCT02526784
- Testing
- degarelix
- Where
- 3 sites in Finland, France and 1 more
- Volunteers
- 120 people
- Sponsor
- Ferring Pharmaceuticals
Glioblastoma Multiforme
A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma
This open-label, multicenter study will evaluate the safety and efficacy of RO5323441 in combination with Avastin (bevacizumab) in patients with recurrent glioblastoma.
- Trial name
- NCT01308684
- Testing
- RO5323441 + bevacizumab [Avastin], bevacizumab [Avastin]
- Where
- 4 sites in Denmark, France and 2 more
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab
This randomized, open-label study will evaluate the safety and efficacy of Avastin (Bevacizumab) added to standard mFOLFOX6 chemotherapy in treatment-naïve patients with Stage IV metastatic colorectal cancer.
- Trial name
- NCT01338558
- Testing
- bevacizumab [Avastin], cetuximab, mFOLFOX6
- Sponsor
- Hoffmann-La Roche
Neoplasms, Breast
A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer
Treatment phase: The purpose of this study is to evaluate the safety and the immune response elicited by a new anti-cancer therapy in patients with breast cancer in remission but who are at high risk of relapse.
- Trial name
- NCT00058526
- Testing
- Immunotherapeutic SB719125 (Primary)
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.